Tongeye Overview

  • Year Founded
  • 2023

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 4

Tongeye General Information

Description

Developer of cell therapy drugs intended for ophthalmic diseases. The company leverages multiple research and development pipelines to transplant unique naive retinal pigment epithelium cells derived from induced pluripotent stem cells to treat dry retinal degeneration with an efficient induction and differentiation method backed by independent intellectual property rights, it has reduced costs, improved accessibility, and accelerated the traditional differentiation cycle, serving clients worldwide to improve vision for patients with dry retinal degeneration.

Contact Information

Website
www.tongeye.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room C201, Number 298 Xueshi Road, Shounan Street
  • Yinzhou District
  • Ningbo, Zhejiang 315832
  • China
+86 020
Primary Industry
Drug Discovery
Corporate Office
  • Room C201, Number 298 Xueshi Road, Shounan Street
  • Yinzhou District
  • Ningbo, Zhejiang 315832
  • China
+86 020

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tongeye Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 23-Sep-2026 Completed Generating Revenue
3. Secondary Transaction - Private 30-Jul-2026 Completed Generating Revenue
2. Early Stage VC 26-Jun-2025 Completed Generating Revenue
1. Seed Round 22-Nov-2023 Completed Startup
To view Tongeye’s complete valuation and funding history, request access »

Tongeye Patents

Tongeye Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026166335-A1 Use of epo in preparation of drug for preventing and treating corneal injury Pending 07-Feb-2025

Tongeye Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Fuzhi Investment Management Venture Capital Minority
DFJ Fund Venture Capital Minority
Jiashan Xingxiang Investment Venture Capital Minority
V Star Capital Venture Capital Minority
To view Tongeye’s complete investors history, request access »

Tongeye FAQs

  • When was Tongeye founded?

    Tongeye was founded in 2023.

  • Where is Tongeye headquartered?

    Tongeye is headquartered in Ningbo, China.

  • What industry is Tongeye in?

    Tongeye’s primary industry is Drug Discovery.

  • Is Tongeye a private or public company?

    Tongeye is a Private company.

  • What is Tongeye’s current revenue?

    The current revenue for Tongeye is .

  • Who are Tongeye’s investors?

    Fuzhi Investment Management, DFJ Fund, Jiashan Xingxiang Investment, and V Star Capital have invested in Tongeye.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process